Regeneron Pharmaceuticals (NQ:REGN)

735.20 +0.39 (+0.05%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2

...

16 17 18 19 20 21 22 23 24

...

66 67 Next >

EYLEA HD® (aflibercept) Injection 8 mg sBLA Accepted for FDA Priority Review for Both the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing in Approved Indications

April 17, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction ↗

April 16, 2025

Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating...

Via Benzinga

Topics Government

Sanofi Asthma Drug Misses Primary Goal, Plans For Pivotal Study ↗

April 15, 2025

Sanofi reports amlitelimab improved lung function in asthma, with new phase 3 trials planned across its respiratory pipeline.

Via Benzinga

Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers

April 15, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Exact Sciences (NASDAQ:EXAS) and its peers.

Via StockStory

Topics Artificial Intelligence

Reflecting On Immuno-Oncology Stocks’ Q4 Earnings: Regeneron (NASDAQ:REGN)

April 14, 2025

Looking back on immuno-oncology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Regeneron (NASDAQ:REGN) and its peers.

Via StockStory

Topics Artificial Intelligence

Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies ↗

April 11, 2025

Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs.

Via Benzinga

Topics Government World Trade

Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline ↗

April 09, 2025

Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs.

Via Benzinga

Topics Government Supply Chain World Trade

These S&P500 stocks are gapping in today's session ↗

April 09, 2025

Stay updated with the S&P500 gap up and gap down stocks on Wednesday. Get a glimpse of the market's movement during today's session.

Via Chartmill

Is Regeneron Pharmaceuticals Gaining or Losing Market Support? ↗

April 09, 2025

Via Benzinga

4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street ↗

April 07, 2025

Via The Motley Fool

Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY)

April 07, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Incyte (NASDAQ:INCY) and the best and worst...

Via StockStory

Topics Artificial Intelligence

3 Growth Stocks That Have Turned $1,000 Into More Than $100,000 in 20 Years ↗

April 05, 2025

Via The Motley Fool

Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks ↗

April 04, 2025

Trump's new tariff move may raise U.S. pharma costs, with analysts warning of risks tied to EU manufacturing and shifting healthcare policies.

Via Benzinga

Topics Government World Trade

In a market where value is scarce, REGENERON PHARMACEUTICALS (NASDAQ:REGN) offers a refreshing opportunity with its solid fundamentals. ↗

April 02, 2025

Uncover the potential of REGENERON PHARMACEUTICALS, an undervalued stock. NASDAQ:REGN maintains a strong financial position and offers an appealing valuation.

Via Chartmill

Retail Traders Mostly Bullish On Biotech Stocks Amid Blow From RFK Jr. Purge On Health Agencies ↗

April 02, 2025

The sector's recent slide follows Peter Marks' resignation last week as the Food and Drug Administration's top vaccine regulator following a clash with Kennedy.

Via Stocktwits

Topics ETFs Government

Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol? ↗

March 31, 2025

The company unveiled promising results for its experimental cholesterol treatment, a daily pill that blocks PCSK9.

Via Investor's Business Daily

$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today ↗

March 28, 2025

Via Benzinga

Sensei Biotherapeutics Reports Favorable Initial Clinical Activity Data For Solnerstotug In Resistant Tumors ↗

March 28, 2025

Sensei Biotherapeutics' solnerstotug shows a 14% ORR in PD-(L)1 resistant tumors and remains well tolerated in early trial data from its Phase 1/2 study.

Via Benzinga

Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)

March 28, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Merck's Biggest Moneymaker Could Get Even Bigger. But Will It Help Downtrodden Shares? ↗

March 27, 2025

The FDA is due to make an approval decision in mid-September for a key product from the top pharma company.

Via Investor's Business Daily

Why Pharma and Biotech Stocks Got Thrashed on Tuesday ↗

March 25, 2025

Via The Motley Fool

What's going on in today's session: S&P500 movers ↗

March 25, 2025

Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Tuesday.

Via Chartmill

Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025

March 25, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Unity Biotechnology Unveils Mixed Data From Study For Diabetes-Related Blindness, Stock Falls ↗

March 24, 2025

Unity diabetes study showing durable vision gains with full 36-week data expected in Q2 2025.

Via Benzinga

Opthea Phase 3 Trial Fails To Meet Primary Endpoint, Faces Financial Uncertainty ↗

March 24, 2025

Opthea's Phase 3 COAST trial for wet AMD did not meet its primary endpoint, raising financial concerns as the company faces potential investor obligations.

Via Benzinga

3 Reasons to Sell REGN and 1 Stock to Buy Instead

March 21, 2025

What a brutal six months it’s been for Regeneron. The stock has dropped 39.3% and now trades at $662.80, rattling many shareholders. This might have investors contemplating their next move.

Via StockStory

Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack

March 20, 2025

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the immuno-oncology stocks, including Natera (NASDAQ:NTRA) and its peers.

Via StockStory

Topics Artificial Intelligence

Price Over Earnings Overview: Regeneron Pharmaceuticals ↗

March 18, 2025

Via Benzinga

2 Large-Cap Stocks with Solid Fundamentals and 1 to Brush Off

March 17, 2025

Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for...

Via StockStory

Friday's session: top gainers and losers in the S&P500 index ↗

March 14, 2025

Curious about the S&P500 stocks that are in motion on Friday? Join us as we explore the top movers within the S&P500 index during today's session.

Via Chartmill

< Previous 1 2

...

16 17 18 19 20 21 22 23 24

...

66 67 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.